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ABSTRACT
Empagliflozin is an inhibitor of the sodium-glucose cotransporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephrotic 
components in the kidneys. SGLT-2 accounts for about 90% of glucose reabsorption into the blood. Blocking SGLT-2 reduces blood glucose by blocking 
glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine. SGLT-2 inhibitors are an optional second-line therapy 
after metformin; they are generally well tolerated with low risk of hypoglycemia. The various compounds differ with respect to their pharmacokinetic 
properties; however, their clinical efficacy appears to be similar. The clinical differences between the various compounds stem from effects other 
than hypoglycemic effects, their safety and side effects profile. The aim of this review was to investigate the different pharmacokinetic studies of 
empagliflozin in a concise way in the form of tables.
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LITERATURE REVIEW
The type 2 diabetes is a chronic metabolic disorder triggered by insulin 
insensitivity and reduced level of insulin secretion. Insulin is a hormone 
that plays a key role in the transport of glucose to organs like the liver. 
Deficit production of insulin enhances the level of glucose in blood [1]. 
In addition to hyperglycemia, it leads to many other complications such 
as hyperlipidemia, hypertension, arthrosclerosis etc. It is estimated that 
there are 171 million people in the world with diabetes in year 2000 
and this is likely to increase up to 366 million by 2030 [2].
The subject of this review is empagliflozin (BI 10773; 1-chloro-4-(β-
d-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yl-oxy)-benzyl]-
benzene; C23H27ClO7; molecular weight 450.9), an orally active, potent 
and selective inhibitor of SGLT2 being studied for the treatment of 
patients with T2DM [3], developed by Boehringer Ingelheim and Eli Lilly 
and Company. Phase III trials of empagliflozin given as monotherapy or in 
combination with oral antidiabetes drugs or insulin reported statistically 
significant and clinically relevant improvements in glycaemic control, 
body weight and systolic blood pressure when compared with placebo 
and active comparators [4]. Adverse events with SGLT2 inhibitors 
include increased rates of genital infection and urinary tract infection, 
which are attributed to elevated urinary glucose levels. More patients on 
empagliflozin than on placebo reported events consistent with genital 
infection; however, events consistent with urinary tract infection were 
comparable in both groups [5]. Empagliflozin is currently progressing 
through phase III clinical trials, while regulatory decisions are awaited 
for marketing applications recently submitted in the USA and Europe.
This review examines the pharmacokinetic characteristics of 
empagliflozin in healthy individuals, and in patients with T2DM treated 
with empagliflozin monotherapy (Table 1). An electronic literature 
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Study design Major outcomes
This study was undertaken to compare the steady state 
pharmacokinetic and pharmacodynamic properties of 
empagliflozin 5 mg twice daily (BID) and 10 mg once daily (QD) 
in healthy subjects. In an open-label, 2-way crossover study, 
subjects (n=16) received empagliflozin 5 mg BID for 5 days and 
empagliflozin 10 mg QD for 5 days in a randomized order, with a 
washout period of≥6 days between each treatment
There were no clinically relevant differences in 
pharmacokinetic or pharmacodynamic properties between 
BID and QD dose regimens of empagliflozin in healthy 
subjects. Both dose regimens were well tolerated [6]
The aim was to investigate the effects of coadministration of 
the SGLT2 inhibitor empagliflozin with the thiazolidinedione 
pioglitazone. In study 1, 20 healthy volunteers received 50 mg of 
empagliflozin alone for 5 days, followed by 50 mg of empagliflozin 
coadministered with 45 mg of pioglitazone for 7 days and 45 mg of 
pioglitazone alone for 7 days in 1 of 2 treatment sequences
These results indicate that pioglitazone and empagliflozin 
can be coadministered without dose adjustments [7]
In a double-blind, placebo-controlled, parallel-group study, Chinese 
patients with T2DM were randomly assigned to receive a single dose 
of empagliflozin 10 or 25 mg or placebo on day 1 and once daily on 
days 3-9
Results with single and multiple doses of empagliflozin 10 and 
25 mg suggest linear pharmacokinetic properties in Chinese 
patients with T2DM, with a safety profile similar to that of 
placebo. Empagliflozin treatment was associated with increases 
in UGE and reductions in FPG compared with placebo [8]
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Table 1: Study design and major outcomes of different studies
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Study design Major outcomes
This was an open-label, crossover study. Patients with type 2 
diabetes mellitus were randomized to receive empagliflozin 25 
mg once daily for 5 days and either and HCTZ 25 mg once daily 
for 4 days followed by HCTZ 25 mg once daily plus empagliflozin 
25 mg once daily for 5 days or TOR 5 mg once daily for 4 days 
followed by TOR 5 mg once daily plus empagliflozin once daily for 
5 days in 1 of 4 sequences, with at least a 7-day washout period 
between treatments. Pharmacokinetic parameters of empagliflozin, 
HCTZ, and TOR were assessed, and standard bioequivalence 
criteria (80-125%) were applied. Tolerability assessments included 
the frequency of adverse events and an investigator assessment of 
global tolerability
No pharmacokinetic drug-drug interaction was observed 
between empagliflozin and HCTZ or TOR [9]
In an open-label, parallel group study, 32 Japanese patients 
with T2DM and different degrees of renal function (n=8 per 
renal function category: Normal renal function, estimated 
glomerular filtration rate [eGFR; Japanese equation] 
≥90 mL/minutes/1.73 m2; mild renal impairment, eGFR of 
60-90 mL/minutes/1.73 m2; moderate renal impairment, eGFR of 
30-<60 mL/minutes/1.73 m2; and severe renal impairment, eGFR 
of 15-<30 mL/minutes/1.73 m2) received a single 25 mg dose of 
empagliflozin
Pharmacokinetic data suggest that no dose adjustment 
of empagliflozin is necessary in Japanese patients with 
T2DM and renal impairment because increases in exposure 
were<2-fold. Urinary glucose excretion decreased with 
increasing renal impairment [10]
In this open-label study, the effect of renal impairment on the 
pharmacokinetics, pharmacodynamics and safety of a 50-mg dose 
of empagliflozin was investigated in 40 subjects, grouped according 
to eGFR
Renal insufficiency resulted in decreased CLR of 
empagliflozin, moderately increased systemic exposure 
and decreased UGE. A single 50 mg dose of empagliflozin 
was well tolerated in subjects with normal renal function 
and any degree of renal impairment. The pharmacokinetic 
results of this study indicate that no dose adjustment 
of empagliflozin is required in patients with renal 
impairment [11]
Two open-labels, randomized, crossover studies were undertaken 
in healthy subjects. In the first study, 18 subjects received the 
following in 1 of 2 randomized treatment sequences: A single 
dose of empagliflozin 25 mg alone and gemfibrozil 600 mg 
BID for 5 days with a single dose of empagliflozin 25 mg on 
the 3rd day. In the second study, 18 subjects received a single 
dose of empagliflozin 10 mg, a single dose of empagliflozin 10 
mg coadministered with a single dose of rifampicin 600 mg, 
and probenecid 500 mg BID for 4 days with a single dose of 
empagliflozin 10 mg on the 2nd day in 1 of 6 randomized treatment 
sequences
Increases in empagliflozin exposure were<2-fold, indicating 
that the inhibition of the OATP1B1/1B3, OAT3 transporter, 
and uridine diphosphate glucuronosyltransferases did not 
has a clinically relevant effect on empagliflozin exposure. 
No dose adjustments of empagliflozin were necessary when 
it was coadministered with gemfibrozil, rifampicin, or 
probenecid [12]
A total of 78 patients were assigned to empagliflozin 10 mg 
(n=16), 25 mg (n=16) or 100 mg (n=30), or placebo (n=16) for 
28 days. Assessments included AEs and pharmacokinetic and 
pharmacodynamic endpoints
Oral administration of empagliflozin at doses of 10, 25, 
or 100 mg once daily over 28 days resulted in significant 
increases in UGE and reductions in blood glucose 
compared with placebo and were well tolerated in 
patients with type 2 diabetes [13]
This randomized, placebo-controlled within dose groups, 
double-blind, single rising dose study investigated the safety, 
tolerability, pharmacokinetics and pharmacodynamics of 1 mg 
to 100 mg doses of empagliflozin in 48 healthy Japanese male 
subjects
In conclusion, 1 mg to 100 mg doses of empagliflozin had 
a good safety and tolerability profile in healthy Japanese 
male subjects. Exposure to empagliflozin was dose 
proportional. The amount and rate of urinary glucose 
excretion were higher with empagliflozin than with the 
placebo and increased with empagliflozin dose [14]
A total of 16 healthy male volunteers received three 
treatments (A, B, and C) in one of two treatment 
sequences (AB then C, or C then AB). In treatment AB, 50 
mg empagliflozin was administered once daily (q.d.) for 
5 days (treatment A), immediately followed by coadministration 
of 50 mg empagliflozin q.d. and 100 mg sitagliptin q.d. 
over 5 days (treatment B). In treatment C, 100 mg sitagliptin 
was administered q.d. for 5 days. A washout period of≥7 days 
separated treatments AB and C
These results indicate that empagliflozin and sitagliptin can 
be coadministered without dose adjustments [15]
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search was performed on Scopus to identify relevant studies using the 
generic name ‘empagliflozin’, without date limits, published as English-
language articles. All publications reporting pharmacokinetic and/or 
pharmacodynamic data on empagliflozinin humans were considered 
for this review (Table 2). 
CONCLUSION
The type 2 diabetes is a chronic metabolic disorder triggered by insulin 
insensitivity and reduced level of insulin secretion. Insulin is a hormone 
that plays a key role in the transport of glucose to organs like the liver. 
Deficit production of insulin enhances the level of glucose in blood [1]. 
In addition to hyperglycemia, it leads to many other complications such 
as hyperlipidemia, hypertension, and atherosclerosis. It is estimated 
that there are 171 million people in the world with diabetes in year 
2000 and this is likely to increase up to 366 million by 2030 [2].
After the literature review, empagliflozin was generally well 
tolerated. Renal impairment, hepatic impairment, heart failure, the 
other investigated drugs, and BMI had no meaningful effect on its 
pharmacokinetics, suggesting that dose adjustment is not required. 
Inspite of the available pharmacokinetic data in literature [3-12] and 
many analytical methods for determination of empagliflozin in tablets 
either alone or in combination with linagliptin or metformin [13-20], 
there are no methods available with full details regarding plasma 
extraction and analysis of empagliflozin in plasma samples to evaluate 
the pharmacokinetic parameters. The author will work on a future 
study dealing with the pharmacokinetic evaluation of empagliflozin 
accompanied with the detailed analytical procedure in collaboration 
with the Center for Drug Research and Development.
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